Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
Jitesh Chauhan,Melanie Grandits,Lais C G F Palhares,Silvia Mele,Mano Nakamura,Jacobo López-Abente,Silvia Crescioli,Roman Laddach,Pablo Romero-Clavijo,Anthony Cheung,Chara Stavraka,Alicia M Chenoweth,Heng Sheng Sow,Giulia Chiaruttini,Amy E Gilbert,Tihomir Dodev,Alexander Koers,Giulia Pellizzari,Kristina M Ilieva,Francis Man,Niwa Ali,Carl Hobbs,Sara Lombardi,Daniël A Lionarons,Hannah J Gould,Andrew J Beavil,Jenny L C Geh,Alastair D MacKenzie Ross,Ciaran Healy,Eduardo Calonje,Julian Downward,Frank O Nestle,Sophia Tsoka,Debra H Josephs,Philip J Blower,Panagiotis Karagiannis,Katie E Lacy,James Spicer,Sophia N Karagiannis,Heather J Bax
DOI: https://doi.org/10.1038/s41467-023-37811-3
2023-04-25
Abstract:Outcomes for half of patients with melanoma remain poor despite standard-of-care checkpoint inhibitor therapies. The prevalence of the melanoma-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) expression is ~70%, therefore effective immunotherapies directed at CSPG4 could benefit many patients. Since IgE exerts potent immune-activating functions in tissues, we engineer a monoclonal IgE antibody with human constant domains recognizing CSPG4 to target melanoma. CSPG4 IgE binds to human melanomas including metastases, mediates tumoricidal antibody-dependent cellular cytotoxicity and stimulates human IgE Fc-receptor-expressing monocytes towards pro-inflammatory phenotypes. IgE demonstrates anti-tumor activity in human melanoma xenograft models engrafted with human effector cells and is associated with enhanced macrophage infiltration, enriched monocyte and macrophage gene signatures and pro-inflammatory signaling pathways in the tumor microenvironment. IgE prolongs the survival of patient-derived xenograft-bearing mice reconstituted with autologous immune cells. No ex vivo activation of basophils in patient blood is measured in the presence of CSPG4 IgE. Our findings support a promising IgE-based immunotherapy for melanoma.